News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Slideshows|July 5, 2018

The Brave New World of Inflammation

Author(s)Natalie Timoshin

The immune-brain loop: a world where more and more clinicians boldly go-and thrive-among new discoveries.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

concussion

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

ByBrandee Grate-Perry, MSW, LCSWA,Mena Mirhom, MD, FAPA

July 27th 2026

2026 Conference Insights: ASCP

ByHeidi Anne Duerr, MPH,Leah Kuntz,Jessica Walters

July 23rd 2026

data

2026 Conference Insights: APA

ByJessica Walters,Leah Kuntz

July 23rd 2026

data

2026 Conference Insights: SIRS

ByJessica Walters

July 23rd 2026

depression

Assessing Antipsychotics as Antidepressant Adjuncts

ByKenneth J. Bender, PharmD, MA

July 21st 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults

Quiet Comfort: New Details on COMP360 Psilocybin Administration Sessions for the Treatment of PTSD

Preventing Alzheimer Disease After Brain Injury: Targeting TNF With XPro1595

Attachment-Based Therapy in Adolescent Substance Users: A Meta-Synthesis of Emotional Isolation and Avoidant Attachment Patterns

Phase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia